Table 1.
Summarised cohort/stratified baseline characteristics of patients receiving biologic drugs, analysed for CD11c expression by qPCR
| Full cohort (n = 75) | Etanercept (n = 50) | Adalimumab (n = 25) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cohort characteristics | NR (n = 34) | R (n = 41) | P value | NR (n = 25) | R (n = 25) | P value | NR (n = 9) | R (n = 16) | P value |
| Gender, female, n (%) | 27 (79.4 %) | 31 (75.6 %) | 0.695a | 20 (80 %) | 20 (80 %) | 1.00a | 7 (77.8 %) | 11 (68.8 %) | 0.629a |
| Age, baseline, years, mean (SD) | 59.3 (12.3) | 53.3 (10.3) | 0.023b | 61.2 (12.2) | 54.86 (11.4) | 0.065b | 54.3 (11.7) | 50.7 (8.2) | 0.258b |
| Concurrent DMARDs, n (%) | 28 (82.4 %) | 36 (90 %) | 0.338a | 22 (88 %) | 21 (84 %) | 0.684a | 6 (66.7 %) | 15 (100 %) | 0.017a |
| Baseline DAS28, median (IQR) | 6.2 (5.4–6.6) | 5.8 (5.5–6.3) | 0.131c | 6.2 (5.8–6.6) | 5.9 (5.5–6.2) | 0.156c | 6.6 (5.6–7.03) | 5.6 (5.3–6) | 0.101c |
| 3 month DAS28, median (IQR) | 5.65 (5.4–6.2) | 2.15 (1.6–2.5) | <0.001c | 5.6 (5.3–5.9) | 2.3 (1.9–3) | <0.001c | 6.6 (5.3–6.8) | 1.95 (1.6–2.2) | <0.001c |
| Baseline TJC, median (IQR) | 16 (10–19) | 13 (10–16) | 0.205c | 14 (10–18) | 13 (10–15) | 0.515c | 18 (16–24) | 13 (10–19) | 0.157c |
| Baseline SJC, median (IQR) | 8.5 (4–13) | 9 (6–13) | 0.701c | 7 (4–11) | 9 (6–13) | 0.268c | 11 (9–15) | 8.5 (6–13) | 0.211c |
| Baseline ESR, median (IQR), n | 33 (14–44), 26 | 18 (14–33), 35 | 0.11c | 32 (23–41), 21 | 18 (10–34), 23 | 0.158c | 34 (10–60), 5 | 20.5 (14–31), 12 | 0.712c |
| Baseline HAQ, median (IQR), n | 2.06 (1.38–2.3), 22 | 1.5 (1.13–2), 32 | 0.026c | 2.1 (1.9–2.3), 17 | 1.4 (1.1–1.6), 19 | 0.006c | 1.9 (1.3–2.1), 5 | 1.8 (1.1–2.4), 13 | 0.96c |
| Tempus™ Blood Tube, n (%) | 21 (61.8 %) | 22 (53.4 %) | 0.48a | 15 (60 %) | 14 (56 %) | 0.774a | 6 (66.67 %) | 8 (50 %) | 0.420a |
aCalculated using chi-square test. bCalculated using two independent samples t test. cCalculated using Wilcoxon-Mann–Whitney test. Samples were grouped according to treatment response. NR non-responders, R responders, DAS28 disease activity score in 28 joints, SJC swollen joint count, TJC tender joint count, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire